Kidney Cancer Clinical Trial
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
Summary
The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.
Eligibility Criteria
Inclusion Criteria:
Histologic confirmation of Renal cell carcinoma (RCC) with a clear cell component
Previous treatment with at least one anti-angiogenic agent
Progressed within 6 months of study enrollment
Subjects should not have had more than 3 prior treatments for locally advanced or metastatic disease
Must have available tumor tissue for submission
Subjects must also meet various laboratory parameters for inclusion
Exclusion Criteria:
Subjects with any active autoimmune disease or a history of known autoimmune disease
Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 39 Locations for this study
La Jolla California, 92093, United States
Los Angeles California, 90024, United States
Los Angeles California, 90048, United States
Stanford California, 94305, United States
Aurora Colorado, 80045, United States
Washington District of Columbia, 20007, United States
Chicago Illinois, 60611, United States
Maywood Illinois, 60153, United States
Indianapolis Indiana, 46202, United States
Kansas City Kansas, 66160, United States
Baltimore Maryland, 21201, United States
Baltimore Maryland, 21287, United States
Boston Massachusetts, 02215, United States
Boston Massachusetts, 02215, United States
Ann Arbor Michigan, 48109, United States
Detroit Michigan, 48201, United States
Minneapolis Minnesota, 55455, United States
Tupelo Mississippi, 38801, United States
Lebanon New Hampshire, 03756, United States
Buffalo New York, 14263, United States
New York New York, 10019, United States
New York New York, 10029, United States
New York New York, 10065, United States
New York New York, 10065, United States
Charlotte North Carolina, 28204, United States
Durham North Carolina, 27710, United States
Cleveland Ohio, 44195, United States
Philadelphia Pennsylvania, 19104, United States
Philadelphia Pennsylvania, 19111, United States
Charleston South Carolina, 29425, United States
Nashville Tennessee, 37203, United States
Nashville Tennessee, 37232, United States
Seattle Washington, 98109, United States
Wauwatosa Wisconsin, 53226, United States
Calgary Alberta, T2N 4, Canada
Moncton New Brunswick, E1C 8, Canada
Halifax Nova Scotia, B3H 2, Canada
London Ontario, N6A 4, Canada
Montreal Quebec, H2L 4, Canada
Helsinki , 00029, Finland
Siena , 53100, Italy
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.